Post‐COVID‐19 co‐morbidity of emerged Lophomonas infection and invasive pulmonary aspergillosis: First case report

Due to long corticosteroid therapy in patients with COVID‐19, in case of cough, dyspnea, and weight loss, emerging pulmonary aspergillosis and lophomoniasis should be ruled out.

Detalles Bibliográficos
Autores principales: Sharifpour, Ali, Zakariaei, Zakaria, Fakhar, Mahdi, Banimostafavi, Elham Sadat, Nakhaei, Maryam, Soleymani, Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462364/
https://www.ncbi.nlm.nih.gov/pubmed/34594552
http://dx.doi.org/10.1002/ccr3.4822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462364/
https://www.ncbi.nlm.nih.gov/pubmed/34594552
http://dx.doi.org/10.1002/ccr3.4822

Ejemplares similares